- Date 21 Nov 2014
- Sectors Life Sciences
Alberto Martinez has joined Napp Pharmaceuticals Limited as its new Managing Director, taking over the role from Dietmar Leitner.
Alberto has worked in the pharmaceutical industry for more than 12 years, most recently as General Manager of Mundipharma Pharmaceuticals S.L (Spain), where he oversaw a seven-fold increase in sales, and the company secured first place in Spain’s ‘Great Place to Work’ survey in two consecutive years. Prior to this, Alberto worked as Marketing Manager at Mundipharma International Limited, having begun his pharmaceutical career as a sales representative with Janssen.
Commenting on his appointment, Alberto said, “It is a unique opportunity and privilege to join Napp as its new Managing Director. Napp has accomplished much over the years and clearly continues to succeed and grow as the healthcare landscape changes. I am committed to ensuring that Napp remains ambitious and agile so that we move from strength to strength in the years to come. It’s also important to me that Napp remains a company with strong values that empower our people to take individual responsibility to overcome challenges and deliver on our promises. I am excited to be a part of Napp’s ongoing success story.”
Napp is a successful and growing UK company based in the heart of the Cambridge science community. Privately owned, Napp is part of a worldwide network of independent associated pharmaceutical companies. Napp’s heritage lies in analgesics, but its more recent successes have included product launches in respiratory medicine and oncology. Alberto joins the company as it prepares to enter the biologics market with the launch of a biosimilar medicine early next year.
Napp Pharmaceuticals Limited is part of the Napp Pharmaceutical Group, a privately owned group of UK companies that is part of a worldwide association of independent companies that have been providing innovative medicines since the 1920s. Napp Pharmaceuticals Limited has been based on the Cambridge Science Park since the early 1980s and, at the end of 2013, was ranked 11th largest pharmaceutical company in the UK based on community prescription sales.1
1. IMS Health, Xponent BPI, MAT December 2013.